Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis

Zhiqiang Qin, Xiao Li, Peng Han, Yuxiao Zheng, Hanyu Liu, Jingyuan Tang, Chengdi Yang, Jianzhong Zhang, Kunpeng Wang, Xiaokang Qi, Min Tang, Wei Wang, Wei Zhang, Zhiqiang Qin, Xiao Li, Peng Han, Yuxiao Zheng, Hanyu Liu, Jingyuan Tang, Chengdi Yang, Jianzhong Zhang, Kunpeng Wang, Xiaokang Qi, Min Tang, Wei Wang, Wei Zhang

Abstract

Background: Previous studies have been conducted to reveal the relationship between androgen receptor CAG polymorphism and risk of prostate cancer, yet the results were elusive and controversial. Thus, this meta-analysis was performed to clarify this association.

Methods: To obtain the relevant available studies, online databases PubMed, Embase, and Web of science were searched until September 1st, 2016. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of such association. Subgroup analyses were conducted based on ethnicity and source of controls. Moreover, Begg's funnel plots and Egger's linear regression test were conducted to test the publication bias.

Results: Overall, our results enrolled 51 studies indicated that significant increased risk of prostate cancer was associated with androgen receptor CAG polymorphism (OR = 0.77, 95% CI: 0.67-0.89). In addition, compared with CAG repeat <20, 22, carriers of ≧20, 22 repeats had decreased risk of prostate cancer (cut-off point = 20: OR = 0.27, 95% CI: 0.13-0.52; cut-off point = 22: OR = 0.82, 95% CI: 0.70-0.97). However, when cut-off point = 23, no significant result was detected in such association (pooled OR = 0.88, 95% CI: 0.63-1.24). When cut-off point is 22, the results were positive only in Asian population (OR = 0.53, 95% CI: 0.32-0.89) in the subgroup analysis by ethnicity. Besides, when the studies were stratified by source of controls, the results were not significant in both the subgroup of population-based controls and hospital-based controls.

Conclusions: This meta-analysis suggested the carriers of short polymorphic CAG repeats might increase susceptibility to prostate cancer, which held potential as a detecting marker of the risk of prostate cancer.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of literature search and selection process.
Figure 2
Figure 2
Forest plots of the association between androgen receptor CAG polymorphism and prostate cancer susceptibility.
Figure 3
Figure 3
Forest plots of the association between androgen receptor CAG polymorphism and prostate cancer susceptibility. (A) Cut-off point  =  22; (B) cut-off point  =  23; (C) cut-off point  =  20.
Figure 4
Figure 4
Forest plots of subgroup analysis of the association between androgen receptor CAG polymorphism and prostate cancer susceptibility in the cut-off point of polymorphic CAG repeat lengths  =  22. (A) Stratified by ethnicity; (B) stratified by source of controls.
Figure 5
Figure 5
Begg's funnel plot of publication bias test. (A) Total studies; (B) cut-off point  =  22; (C) cut-off point  =  23; (D) cut-off point  =  20.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
    1. Recine F, Sternberg CN. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol 2015;4:355–64.
    1. Discacciati A, Wolk A. Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res 2014;202:27–37.
    1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859–64.
    1. Lai GY, Giovannucci EL, Pollak MN, et al. Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes Control 2014;25:625–32.
    1. McGregor SE, Courneya KS, Kopciuk KA, et al. Case-control study of lifetime alcohol intake and prostate cancer risk. Cancer Causes Control 2013;24:451–61.
    1. Nelson WG, Demarzo AM, Yegnasubramanian S. The diet as a cause of human prostate cancer. Cancer Treat Res 2014;159:51–68.
    1. Eeles R, Goh C, Castro E, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 2014;11:18–31.
    1. Kantoff P, Giovannucci E, Brown M. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochim Biophys Acta 1998;1378:C1–5.
    1. Knoke I, Allera A, Wieacker P. Significance of the CAG repeat length in the androgen receptor gene (AR) for the transactivation function of an M780I mutant AR. Hum Genet 1999;104:257–61.
    1. Li J, Mercer E, Gou X, et al. Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes. Am J Cancer Res 2013;3:127–51.
    1. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997;94:3320–3.
    1. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105–14.
    1. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
    1. Guo SW, Thompson EA. Performing the exact test of Hardy–Weinberg proportion for multiple alleles. Biometrics 1992;48:361–72.
    1. Gomez R, Torres-Sanchez L, Camacho-Mejorado R, et al. Androgen receptor CAG polymorphism and sporadic and early-onset prostate cancer among Mexican men. J Hum Genet 2016;61:781–6.
    1. Yoo S, Pettersson A, Jordahl KM, et al. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev 2014;23:2027–31.
    1. Alptekin D, Izmirli M, Bayazit Y, et al. Evaluation of the effects of androgen receptor gene trinucleotide repeats and prostate-specific antigen gene polymorphisms on prostate cancer. Genet Mol Res 2012;11:1424–32.
    1. Risio M, Venesio T, Kolomoets E, et al. Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Cancer Epidemiol 2011;35:e18–24.
    1. Nicolaiew N, Cancel-Tassin G, Azzouzi AR, et al. Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol 2009;160:101–6.
    1. Andersson P, Varenhorst E, Soderkvist P. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J Cancer 2006;42:2833–7.
    1. Salinas CA, Austin MA, Ostrander EO, et al. Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate 2005;65:58–65.
    1. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14:1262–9.
    1. Forrest MS, Edwards SM, Houlston R, et al. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 2005;8:95–102.
    1. Balic I, Graham ST, Troyer DA, et al. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 2002;168:2245–8.
    1. Chen C, Lamharzi N, Weiss NS, et al. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11(10 pt 1):1033–40.
    1. Gsur A, Preyer M, Haidinger G, et al. Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 2002;23:1647–51.
    1. Mononen N, Ikonen T, Autio V, et al. Androgen receptor CAG polymorphism and prostate cancer risk. Hum Genet 2002;111:166–71.
    1. Latil AG, Azzouzi R, Cancel GS, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130–7.
    1. Miller EA, Stanford JL, Hsu L, et al. Polymorphic repeats in the androgen receptor gene in high-risk sibships. Prostate 2001;48:200–5.
    1. Modugno F, Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001;7:3092–6.
    1. Xue W, Irvine RA, Yu MC, et al. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 2000;60:839–41.
    1. Correa-Cerro L, Wohr G, Haussler J, et al. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French–German population. Eur J Hum Genet 1999;7:357–62.
    1. Edwards SM, Badzioch MD, Minter R, et al. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer 1999;84:458–65.
    1. Stanford JL, Just JJ, Gibbs M, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57:1194–8.
    1. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997;94:3320–3.
    1. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166–70.
    1. Hakimi JM, Schoenberg MP, Rondinelli RH, et al. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997;3:1599–608.
    1. Irvine RA, Yu MC, Ross RK, et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937–40.
    1. Mao X, Li J, Xu X, et al. Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer. AM J Cancer Res 2014;4:886–96.
    1. Zhai XL, Qu XW, Guo L, et al. Correlation study between the polymorphism of repetitive sequence in gene CAG of androgen receptor and the occurrence and progression of prostate cancer. Asian Pac J Trop Med 2014;7:301–4.
    1. Soni A, Bansal A, Mishra AK, et al. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population. Genet Test Mol Biomarkers 2012;16:835–40.
    1. Ashtiani ZO, Hasheminasab SM, Ayati M, et al. GSTT1 and CAG repeat length of androgen receptor gene polymorphisms associated with risk of prostate cancer in Iranian patients? Pathol Oncol Res 2011;17:269–75.
    1. Das K, Cheah PY, Lim PL, et al. Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer. Cancer Lett 2008;268:340–7.
    1. Mittal RD, Mishra DK, Thangaraj K, et al. Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population? Steroids 2007;72:335–41.
    1. Krishnaswamy V, Kumarasamy T, Venkatesan V, et al. South Indian men with reduced CAG repeat length in the androgen receptor gene have an increased risk of prostate cancer. J Hum Genet 2006;51:254–7.
    1. Okugi H, Nakazato H, Matsui H, et al. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. Cancer Detect Prev 2006;30:262–8.
    1. Mishra D, Thangaraj K, Mandhani A, et al. Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population? Clin Genet 2005;68:55–60.
    1. Huang SP, Chou YH, Chang WS, et al. Androgen receptor gene polymorphism and prostate cancer in Taiwan. J Formos Med Assoc 2003;102:680–6.
    1. Hsing AW, Chokkalingam AP, Gao YT, et al. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2002;11:337–41.
    1. Hsing AW, Gao YT, Wu G, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000;60:5111–6.
    1. Akinloye O, Gromoll J, Simoni M. Variation in CAG and GGN repeat lengths and CAG/GGN haplotype in androgen receptor gene polymorphism and prostate carcinoma in Nigerians. Br J Biomed Sci 2011;68:138–42.
    1. Lange EM, Sarma AV, Ray A, et al. The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study. J Hum Genet 2008;53:220–6.
    1. Gilligan T, Manola J, Sartor O, et al. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African–American population. Clin Prostate Cancer 2004;3:98–103.
    1. Silva NB, Koff WJ, Biolchi V, et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest 2008;26:74–80.
    1. Lindstrom S, Zheng SL, Wiklund F, et al. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate 2006;66:1729–43.
    1. Santos ML, Sarkis AS, Nishimoto IN, et al. Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population. Cancer Detect Prev 2003;27:321–6.
    1. Paz-Y-Mino C, Robles P, Salazar C, et al. Positive association of the androgen receptor CAG repeat length polymorphism with the risk of prostate cancer. Mol Med Rep 2016;14:1791–8.
    1. Kuasne H, Rodrigues IS, Fuganti PE, et al. Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer. Cancer Invest 2010;28:917–24.
    1. Price DK, Chau CH, Till C, et al. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J Urol 2010;184:2297–302.
    1. Sieh W, Edwards KL, Fitzpatrick AL, et al. Genetic susceptibility to prostate cancer: prostate-specific antigen and its interaction with the androgen receptor (United States). Cancer Causes Control 2006;17:187–97.
    1. Cicek MS, Conti DV, Curran A, et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 2004;59:69–76.
    1. Li C, Gronberg H, Matsuyama H, et al. Difference between Swedish and Japanese men in the association between AR CAG repeats and prostate cancer suggesting a susceptibility-modifying locus overlapping the androgen receptor gene. Int J Mol Med 2003;11:529–33.
    1. Chang BL, Zheng SL, Hawkins GA, et al. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet 2002;110:122–9.
    1. Panz VR, Joffe BI, Spitz I, et al. Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men. Endocrine 2001;15:213–6.
    1. Ekman P, Gronberg H, Matsuyama H, et al. Links between genetic and environmental factors and prostate cancer risk. Prostate 1999;39:262–8.
    1. Zeegers MP, Kiemeney LA, Nieder AM, et al. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev 2004;13(11 pt 1):1765–71.
    1. Gu M, Dong X, Zhang X, et al. The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis. Mol Biol Rep 2012;39:2615–24.
    1. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834–45.
    1. Ding D, Xu L, Menon M, et al. Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate 2004;58:23–32.
    1. Irvine RA, Ma H, Yu MC, et al. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000;9:267–74.
    1. Krausz C. An encore for the repeats: new insights into an old genetic variant. J Clin Endocrinol Metab 2012;97:764–7.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다